Survodutide

Background

Survodutide (BI 456906) is an investigational, once-weekly peptide therapeutic in the GLP-1/glucagon dual-agonist class. It was developed by Boehringer Ingelheim as a long-acting analog derived from glucagon, with engineering to add potent GLP-1 receptor activity and extend circulation time through albumin binding.[3][4] The candidate was selected from a larger discovery program of dual GCGR/GLP-1R agonists after biomarker-based pharmacological profiling identified favorable activity for metabolic disease development.[4]

The therapeutic rationale for survodutide is that GLP-1 receptor agonism reduces energy intake and improves glycemia, while glucagon receptor agonism may increase energy expenditure and contribute to greater weight loss than GLP-1 receptor agonism alone.[2][3] This “balanced” dual agonism has been positioned for obesity, type 2 diabetes, and liver disease associated with metabolic dysfunction, including MASH.[3][7][10][12]

Mechanism of action

Survodutide is a dual agonist at the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R).[1][3][4] Preclinical and translational work supports a design intended to preserve glucagon-like structural features while conferring clinically relevant GLP-1R activity.[3][4] The molecule is described as a 29-amino-acid peptide with a C18 diacid lipid moiety that promotes albumin binding and supports weekly subcutaneous dosing.[3]

At a mechanistic level, GLP-1R activation is expected to slow gastric emptying, reduce appetite, and improve glucose-dependent insulin secretion, whereas GCGR activation is expected to promote lipolysis and increase energy expenditure, potentially offsetting glucagon’s tendency to raise glucose when used alone.[2][3] The clinical hypothesis for survodutide is that the combination may produce additive or synergistic weight loss with glycemic benefit.[3][5]

Biomarker and pharmacology studies used during candidate selection support a profile consistent with dual receptor engagement and helped prioritize survodutide over other analogs for clinical development.[4] However, the published human dataset still reflects an investigational product rather than a mechanism fully validated by outcomes trials.

Evidence summary

The most cited clinical evidence comes from two phase 2 randomized trials in obesity and type 2 diabetes, plus early phase liver-disease studies.

In overweight/obesity, a phase 2, multicenter, randomized, double-blind, placebo-controlled dose-finding study (NCT04667377) enrolled 387 adults; 386 were treated and 384 were in the full analysis set.[2] Participants received once-weekly subcutaneous survodutide 0.6, 2.4, 3.6, or 4.8 mg, or placebo, for 46 weeks with stepwise dose escalation.[2] Mean body-weight change at week 46 showed a dose-response pattern: −6.2% with 0.6 mg, −12.5% with 2.4 mg, −13.2% with 3.6 mg, and −14.9% with 4.8 mg, versus −2.8% with placebo.[2] Among participants who reached and stayed on 4.8 mg, weight loss was 18.7% at week 46.[2] The study also reported high proportions achieving clinically meaningful thresholds of weight loss, including 54.7% reaching at least 15% loss at 4.8 mg versus 5.6% on placebo.[2]

In type 2 diabetes, a phase 2 randomized, double-blind, placebo-controlled study compared multiple once-weekly and twice-weekly survodutide doses with placebo and open-label semaglutide in 413 randomized participants.[5][9] The trial enrolled adults aged 18–75 years with HbA1c 7.0%–10.0% on metformin and BMI 25–50 kg/m².[5] After 16 weeks, HbA1c fell dose-dependently by up to about 1.7 percentage points in the highest-dose groups, and body weight decreased by up to 8.7% with the highest weekly dose; lower-dose survodutide produced glycemic reductions similar to semaglutide in some comparisons.[5][9] The publication supports clinically meaningful short-term improvements in both glycemia and body weight, but treatment duration was brief and not designed for hard outcomes.[5][9]

For MASH, a phase 2 dose-finding study (NCT04771273) randomized 293 participants with MASH and fibrosis to once-weekly survodutide 2.4 mg, 4.8 mg, 6.0 mg, or placebo for 48 weeks, and early congress reporting described histologic and metabolic signals, but full peer-reviewed outcomes remain limited in the sources available here.[12] For cirrhosis, a multinational open-label phase 1 trial has been reported in compensated and decompensated disease, reflecting early safety exploration rather than efficacy proof.[1]

A post hoc analysis from the obesity phase 2 trial reported improvements in blood pressure associated with treatment-related weight loss, supporting cardiometabolic effects but not establishing cardiovascular outcome benefit.[8] Phase 3 programs are ongoing, including SYNCHRONIZE obesity trials and SYNCHRONIZE-CVOT.[7][10]

Clinical and research uses

Survodutide is not approved for any indication, but it is being investigated for obesity, type 2 diabetes, MASH with fibrosis, and cardiovascular safety/outcomes in overweight and obesity.[5][7][10][12] Published phase 2 data support weight-loss and HbA1c-lowering activity, while phase 3 programs are intended to define durability, safety, and cardiovascular risk profile.[7][10]

Current research use is therefore investigational only. There is no established off-label clinical role supported by regulatory labeling or completed outcomes trials.

Dosing context

Published studies used once-weekly subcutaneous administration as the principal regimen.[2][3][5][10] In obesity, the phase 2 study evaluated 0.6, 2.4, 3.6, and 4.8 mg weekly over 46 weeks, with a 20-week rapid dose-escalation period followed by maintenance.[2] In diabetes, weekly doses up to 0.3, 0.9, 1.8, and 2.7 mg were studied, as well as twice-weekly regimens of 1.2 and 1.8 mg, with a semaglutide comparator arm.[5] Phase 3 obesity trials were designed as once-weekly subcutaneous studies.[10]

These are study regimens only and should not be interpreted as prescribing recommendations. No approved dosing, titration, or substitution guidance exists in the United States or European Union.

Safety profile

The dominant adverse effects reported across trials are gastrointestinal, consistent with the GLP-1 receptor component of the mechanism.[2][5][6] Nausea, vomiting, diarrhea, decreased appetite, and treatment discontinuation due to adverse events were common enough to be a central limitation of development; a narrative review specifically notes notable gastrointestinal toxicity and discontinuation in phase 2 studies.[6] In the obesity trial, adverse events were frequent across active-treatment groups, although the abstract excerpt provided in the search results does not include the full breakdown.[2]

Blood-pressure reductions have been observed post hoc, which may be favorable in some patients but could be relevant if symptomatic hypotension or volume depletion occurs during dose escalation.[8] For liver-disease programs, safety in compensated and decompensated cirrhosis has been explored only in an early phase 1 setting.[1]

Contraindications are not formally established in labeling because no approved product exists. In practice, trial programs generally exclude patients with conditions that could confound safety interpretation or increase risk, and class-based caution is commonly applied for severe gastrointestinal disease, hypersensitivity, and acute pancreatitis risk, but these are inference-based rather than survodutide-specific label contraindications.[5][7][10] No regulatory contraindication list is available from FDA or EMA for survodutide.

Regulatory status

Survodutide remains investigational and has no FDA-approved or EMA-approved indication as of the current evidence base provided here.[7][10][12] The most advanced publicly described programs are phase 3 obesity studies, including SYNCHRONIZE-1, SYNCHRONIZE-2, and SYNCHRONIZE-CVOT.[7][10] The compound has also been studied in phase 2 MASH and type 2 diabetes trials and in early safety studies in cirrhosis.[1][5][12]

No US or EU marketing authorization, prescribing information, or approved contraindication profile is available at this time.